Enhanced mitochondrial potential in
carcinoma cells is an important characteristic of
cancer. It is of great current interest to develop a radiotracer that is sensitive to mitochondrial potential changes at the early stage of
tumor growth. In this report, we present the synthesis and evaluation of (64)Cu-labeled
Lissamine rhodamine B (LRB), (64)Cu(DOTA-LRB) (
DOTA-LRB = 2-(6-(diethylamino)-3-(diethyliminio)-3H-xanthen-9-yl)-5-(N-(2-(2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclo-dodecan-1-yl)acetamido)ethyl)sulfamoyl)
benzenesulfonate) as a new radiotracer for imaging
tumors in athymic nude mice bearing U87MG human
glioma xenografts by positron emission tomography (PET). We also explored its localization mechanism using Cu(
DOTA-LRB) as the
fluorescent probe in both the U87MG human
glioma cell line and the cultured primary U87MG
glioma cells. It was found that (64)Cu(DOTA-LRB) had the highest
tumor uptake (6.54 ± 1.50, 6.91 ± 1.26, 5.68 ± 1.13, 7.58 ± 1.96, and 5.14 ± 1.50%ID/g at 0.5, 1, 2, 4, and 24 h postinjection, respectively) among many (64)Cu-labeled organic
cations evaluated in the same animal model. The cellular staining study indicated that Cu(
DOTA-LRB) was able to localize in mitochondria of U87MG
glioma cells due to the enhanced negative mitochondrial potential. This statement is completely supported by the results from decoupling experiment with carbonylcyanide-m-chlorophenylhydrazone (
CCCP). MicroPET data showed that the U87MG
glioma tumors were clearly visualized as early as 30 min postinjection with (64)Cu(DOTA-LRB). (64)Cu(DOTA-LRB) remained stable during renal excretion, but underwent extensive degradation during hepatobiliary excretion. On the basis of the results from this study, it was concluded that (64)Cu(DOTA-LRB) represents a new class of promising PET radiotracers for noninvasive imaging of the MDR-negative
tumors.